This clinical trial is focused on studying a rare blood disease called Paroxysmal Nocturnal Hemoglobinuria (PNH). PNH is a condition where red blood cells break down too early, leading to various health issues. The study is comparing two treatments: Crovalimab and Eculizumab. Crovalimab is a solution that can be given either through an injection under the skin or directly into a vein, while Eculizumab is given through a vein. Both treatments are designed to help manage the symptoms of PNH by preventing the breakdown of red blood cells.

The purpose of this study is to evaluate how effective and safe Crovalimab is compared to Eculizumab in patients who have not been treated with similar medications before. Participants in the study will receive either Crovalimab or Eculizumab and will be monitored over a period of time to see how well the treatments work in preventing blood transfusions and controlling the breakdown of red blood cells. The study will also look at other factors such as the stability of hemoglobin levels, which is a protein in red blood cells that carries oxygen, and any side effects that may occur.

Throughout the study, researchers will collect information on how patients respond to the treatments, including any changes in fatigue levels, which is a common symptom of PNH. They will also monitor for any reactions at the injection site or other side effects. The study aims to provide valuable insights into the management of PNH and help determine the best treatment options for patients with this condition.